Browsing by Author Paksec, Lisa

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2011Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast CancerCoates, Alan; Gebski, Val; Grimison, Peter; Stockler, Martin; Wilcken, Nicholas; Zannino, Diana; Ackland, Stephen; Byrne, Michael J.; Fitzharris, B; Fong, A.; Forbes, John; Francis, Prudence; Gainford, Corona; Harvey, V; Nowak, Anna; Paksec, Lisa; Simes, John; Sourjina, Tatiana; Van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials CentreCapecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer, Journal of Clinical Oncology, vol.29, 34, 2011,pp 4498-4504
2006A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatmentCoates, Alan; Gebski, Val; Simes, Robert John; Sourjina, Tatiana; Stockler, Martin; Ackland, Stephen P.; Byrne, Michael J.; Finch, K; Fitzharris, B; Forbes, John F.; Frances, P; Harvey, V; Kato-Fong, A; Lindsay, Dianne; Paksec, Lisa; van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment, Breast Cancer Research and Treatment, vol.100, Supplement 1,pp S278-S278